The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

1965 - On 5th February, the Company entered into an agreement with C.H. Boehringer Sohn, Ingelheim ... drug-delivery systems in the country. - For German Remedies, the tie-up is one in a ...

Boehringer Ingelheim has taken an option on ... which are the target of around a third of all marketed drugs, and Boehringer adds to a growing list of partners that also includes AbbVie ...

German drugmaker Boehringer Ingelheim has its first regulatory ... but would not diclose the list price for the drug, saying simply that the company is "working closely with insurance companies ...

When the Inflation Reduction Act was signed into law in 2022, it authorized a number of initiatives aimed at reducing the ...

Among patients with Crohn's disease, a multicenter prospective cohort study found that anti-TNF therapy failed to achieve remission at 3 years in about two-thirds of cases, and that high drug ...

Last year, Gilead only featured (PDF) once, taking second place on the list of companies ANZ patient ... the leaderboards and were replaced by Boehringer Ingelheim and AstraZeneca.

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S ... s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.